A longitudinal single-cell atlas of anti-tumour necrosis factor treatment in inflammatory bowel disease.

Autor: Thomas T; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Centre for Human Genetics, University of Oxford, Oxford, UK.; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK., Friedrich M; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK., Rich-Griffin C; Centre for Human Genetics, University of Oxford, Oxford, UK., Pohin M; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Agarwal D; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Pakpoor J; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.; Centre for Human Genetics, University of Oxford, Oxford, UK.; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK., Lee C; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Tandon R; University College London Hospitals NHS Foundation Trust, London, UK., Rendek A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Aschenbrenner D; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK., Jainarayanan A; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Voda A; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Siu JHY; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Sanches-Peres R; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Nee E; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Sathananthan D; University of Adelaide, Adelaide, Australia.; Lyell McEwin Hospital, Adelaide, Australia., Kotliar D; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Todd P; Centre for Human Genetics, University of Oxford, Oxford, UK., Kiourlappou M; Centre for Human Genetics, University of Oxford, Oxford, UK., Gartner L; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK., Ilott N; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Issa F; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Hester J; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Turner J; Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK., Nayar S; Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and NIHR Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Tissue Analytics, Institute of Translational Medicine, University of Birmingham, Birmingham, UK., Mackerodt J; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Zhang F; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.; Center for Health AI, University of Colorado Anschutz, Anschutz, CO, USA., Jonsson A; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Brenner M; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Raychaudhuri S; Broad Institute of MIT and Harvard, Cambridge, MA, USA.; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA., Kulicke R; Celsius Therapeutics, Cambridge, MA, USA., Ramsdell D; Celsius Therapeutics, Cambridge, MA, USA., Stransky N; Celsius Therapeutics, Cambridge, MA, USA., Pagliarini R; Celsius Therapeutics, Cambridge, MA, USA., Bielecki P; Celsius Therapeutics, Cambridge, MA, USA., Spies N; Celsius Therapeutics, Cambridge, MA, USA., Marsden B; Centre for Human Genetics, University of Oxford, Oxford, UK., Taylor S; Centre for Human Genetics, University of Oxford, Oxford, UK., Wagner A; Department of Electrical Engineering and Computer Science, University of California, Berkeley, Berkeley, CA, USA.; The Center for Computational Biology, University of California, Berkeley, Berkeley, CA, USA., Klenerman P; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK., Walsh A; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK., Coles M; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Jostins-Dean L; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Powrie FM; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK., Filer A; Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and NIHR Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.; Birmingham Tissue Analytics, Institute of Translational Medicine, University of Birmingham, Birmingham, UK., Travis S; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. simon.travis@kennedy.ox.ac.uk.; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK. simon.travis@kennedy.ox.ac.uk.; NIHR Oxford Biomedical Research Centre, Oxford, UK. simon.travis@kennedy.ox.ac.uk., Uhlig HH; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK. holm.uhlig@ndm.ox.ac.uk.; NIHR Oxford Biomedical Research Centre, Oxford, UK. holm.uhlig@ndm.ox.ac.uk.; Department of Paediatrics, University of Oxford, Oxford, UK. holm.uhlig@ndm.ox.ac.uk., Dendrou CA; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. calliope.dendrou@kennedy.ox.ac.uk.; Centre for Human Genetics, University of Oxford, Oxford, UK. calliope.dendrou@kennedy.ox.ac.uk.; NIHR Oxford Biomedical Research Centre, Oxford, UK. calliope.dendrou@kennedy.ox.ac.uk., Buckley CD; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. christopher.buckley@kennedy.ox.ac.uk.; Translational Gastroenterology & Liver Unit, John Radcliffe Hospital, Headington, Oxford, UK. christopher.buckley@kennedy.ox.ac.uk.; Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK. christopher.buckley@kennedy.ox.ac.uk.; NIHR Oxford Biomedical Research Centre, Oxford, UK. christopher.buckley@kennedy.ox.ac.uk.

Publikováno v: Nature immunology [Nat Immunol] 2024 Nov; Vol. 25 (11), pp. 2152-2165. Date of Electronic Publication: 2024 Oct 22.

Primary cilia sense glutamine availability and respond via asparagine synthetase.

Autor: Steidl ME; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy.; Ph.D Program in Molecular and Cellular Biology, Vita-Salute San Raffaele University, Milan, Italy., Nigro EA; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Nielsen AK; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy.; Ph.D Program in Molecular and Cellular Biology, Vita-Salute San Raffaele University, Milan, Italy., Pagliarini R; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Cassina L; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Lampis M; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy.; Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland., Podrini C; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Chiaravalli M; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Mannella V; Center for Omics Sciences, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Distefano G; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Yang M; MRC, Cancer Unit Cambridge, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.; CECAD Research Center, Cologne, Germany., Aslanyan M; Department of Human Genetics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Musco G; Biomolecular Nuclear Magnetic Resonance Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy., Roepman R; Department of Human Genetics and Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands., Frezza C; MRC, Cancer Unit Cambridge, Hutchison/MRC Research Centre, University of Cambridge, Cambridge, UK.; CECAD Research Center, Cologne, Germany., Boletta A; Molecular Basis of Cystic Kidney Disorders Unit, Division of Genetics and Cell Biology, IRCCS, San Raffaele Scientific Institute, Milan, Italy. boletta.alessandra@hsr.it.

Publikováno v: Nature metabolism [Nat Metab] 2023 Mar; Vol. 5 (3), pp. 385-397. Date of Electronic Publication: 2023 Mar 06.

Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer.

Autor: Gao X; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.; Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, Charleston, South Carolina., Wang Y; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Ribeiro CF; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Manokaran C; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Chang H; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Von T; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Rodrigues S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Cizmecioglu O; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Jia S; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Korpal M; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Korn JM; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Wang Z; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Schmit F; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Jiang L; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pagliarini R; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Yang Y; Oncology Disease Area, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Sethi I; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Signoretti S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Yuan GC; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Loda M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.; Department of Pathology, Harvard Medical School, Boston, Massachusetts., Zhao JJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Roberts TM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Molecular cancer research : MCR [Mol Cancer Res] 2022 May 04; Vol. 20 (5), pp. 673-685.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.